Tag Archives: Biotech IPO

An 18 Month Journey From Inception To IPO
November 16, 2022

By Ivana Magovčević-Liebisch PhD, JD, CEO of VIGIL NEUROSCIENCE, as part of the From The Trenches feature of LifeSciVC Compared to most industries, biotech life cycles are lengthy. From R&D and clinical development to regulatory approval, it takes an average

Leave a comment

In Defense Of Early Stage Biotech IPOs
March 28, 2022

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market. I’ve read a good deal of venting covering this theme, including comments about VCs

Leave a comment

Innovation Ecosystem: A Year Of Risk-Off Correlations
March 21, 2022

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing both the emerging tech and biotech sectors alike. Last year, generalists in many ways capitulated

Leave a comment

Biotech’s Relevancy Challenge In An Expanding Universe
June 1, 2021

The universe of public biotech companies has been growing for a decade, and increasingly so in the past few years as the IPO market has flourished. Hundreds of young aspiring biotechs have tapped into the public equity markets, swelling the

Leave a comment

Evolution Of The Biotech IPO Markets From Busted To Booming
September 21, 2020

In the excitement of today’s biotech IPO market, and the bullish period since 2013, it’s almost hard to remember how painful the equity capital markets were back in the day. When I began my career in venture capital in 2004,

Leave a comment

Value Creation And Destruction: Dispersion of Performance In Biotech IPOs
April 17, 2020

The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year. And the queue for companies with active S1’s on file is

Leave a comment

2018’s Biotech IPO Bonanza: View From the After Market
October 17, 2018

2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits

Leave a comment

Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
October 5, 2018

The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market

Leave a comment

The Incredible Expanding Universe of Biotech Stocks
September 21, 2018

The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint. It’s been well appreciated by market analysts that the universe of U.S.

Leave a comment

IPO: A Go-Go Or A No-No?
September 4, 2018

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Elon Musk has a flare for the dramatic, shocking Wall Street (and others) the first week

Leave a comment

This Time May Be Different: Today’s Biotech Market In Context
January 7, 2016

The past five years have been the greatest bull run in the history of the biotech industry. Stock market outperformance, significant fundraising levels both private and public, more IPOs in this window than ever before, and huge volumes of M&A.


The Churchillian Biotech IPO: This Is Not Even The Beginning Of The End
November 2, 2015

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. For a great company, an IPO is a financing event. Not an exit. Not the end. This is important to

Leave a comment

Biotech IPO Performance: Discerning Market Or Rising Tide?
March 20, 2015

As anyone following the biotech sector knows, the market for new public offerings has been incredibly strong over the past couple years. And the larger cap stocks in the sector have also outperformed, propelled by product launches and exciting clinical

Leave a comment

Tortoise & Hare Revisited: “Time To IPO” For VC-Backed Startups
February 24, 2015

Getting a drug from discovery to market requires more than a dozen years, so you just can’t do biotech in a 10-year venture fund – it just takes too long, right?  Fortunately, wrong.  The data just don’t support this premise, although this

Leave a comment

Tradeoffs and Timing: IPO vs. M&A Decision Making in Biotech
April 2, 2014

In light of the continued interest in biotech IPOs by the capital markets, there’s probably not a venture-backed biotech boardroom that hasn’t been discussing the merits of going public. Whether warranted or not, taking a company public via an IPO

1 Comment